Novartis AG vs Opendoor Technologies Inc — how do they compare? Novartis AG trades at $143.26 (market cap $268.57B), while Opendoor Technologies Inc trades at $2.25 (market cap $2.22B). The key difference: Novartis AG is far larger — about 121× Opendoor Technologies Inc's market cap, and Novartis AG pays a 3.31% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Opendoor Technologies Inc for 33 Days on average.
| NVS | OPEN | |
|---|---|---|
Market Cap | $268.57B | $2.22B |
Volume | 1,532,573 | 28,705,892 |
Sector | Health | Real Estate |
52-Week High | $168.62 | $9.37 |
52-Week Low | $121.80 | $2.27 |
Typical Hold Time | 82 Days | 33 Days |
Enterprise Value | $309.89B | $3.29B |
Dividend Yield | 3.31% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Opendoor Technologies (OPEN) trades at $2.27 with no recent price movement, reflecting ongoing investor caution. The stock shows bearish technical signals with most moving averages and oscillators indicating selling pressure. Fundamentally, the company continues to struggle with profitability, posting a -46.74% net income margin and -$1.30B net loss in 2025 despite $4.37B revenue. Recent news highlights the company's mortgage expansion strategy and ongoing challenges in the housing market.
While analyst consensus suggests significant upside potential with a $4.92 price target, the company faces substantial execution risks amid persistent losses and high debt levels. The path to profitability remains uncertain, with revenue declining from $15.6B in 2022 to $4.4B in 2025. Investors should weigh the discounted valuation against ongoing operational challenges in the volatile housing sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →